ClinicalTrials.gg
CompletedNCT00867932Updated Oct 31, 2018Results posted

Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 4 interventional study of Eculizumab in Hemoglobinuria, Paroxysmal, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 3 sites in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-10-31.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.

Enrollment
17th of 18
7 · median 37
Started
2009
the only one that year
Phase 4
2 of 18
none open now
Registered
6th of 18
by date
Lead sponsor
8 of 18
Alexion Pharmaceuticals, Inc.

Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 17th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 4, and was the 6th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →

About eculizumab

eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal as a file.
02

Study summary

The primary objective of this study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) parameter estimates of eculizumab to confirm the dose regimens for pediatric and adolescent participants with PNH.

Read the detailed description

This was an open-label, multi-center study of eculizumab administered to approximately 6 to 8 pediatric and adolescent participants aged 2 to 17 years with PNH. There were 3 periods in this study (screening, treatment, and post-treatment) with the treatment period having 2 dosing phases (induction and maintenance). If all screening criteria were met, the participant was eligible to enter the treatment period of the study after receiving Neisseria meningitidis (N. men), Streptococcus pneumoniae (S. pneumo), and Haemophilus influenzae (H. influ) vaccinations at least 14 days prior to first dose of study drug, or was vaccinated and received treatment with appropriate antibiotics until 14 days after the vaccinations. Participants received eculizumab intravenously (IV) based on their weight. Eculizumab was administered via an IV infusion at a rate of 5 to 10 milliliters (mL) per kilogram (kg) per hour (hr) (mL/kg/hr) for at least 25 minutes. The planned duration of treatment was 12 weeks with a 4-week induction phase and an 8-week maintenance phase. At the Investigator's and parents/legal guardian's discretion, participants who completed this study with eculizumab could continue treatment with commercially available eculizumab (Soliris®) and were followed in the Soliris® PNH Registry. Participants who stopped study participation before study completion or who did not continue with Soliris® treatment at the completion of the study were followed for 8 weeks and monitored for signs and symptoms of serious hemolysis.

03

Conditions studied

  • Hemoglobinuria, Paroxysmal

Keywords

  • Alexion
  • Eculizumab
  • Paroxysmal Nocturnal Hemoglobinuria
  • PNH
  • Soliris
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants between 2 and 17 years of age;
  • Diagnosed with PNH;
  • Participants with ≥ 5% glycosylphosphatidylinositol-deficient red blood cells or granulocytes as confirmed by flow cytometry;
  • Participants must have shown evidence of hemolytic anemia as documented by lactate dehydrogenase greater than the or at least 1 transfusion in the past 2 years for anemia or anemia related symptoms;
  • Written from a parent/guardian;
  • Negative pregnancy test for females of child bearing potential at screening;
  • Sexually active females must have documented a reliable and medically approved method of ;
  • Participant must have been vaccinated against N. men, S. pneumo, and H. influ at least 14 days prior to study drug initiation or received antibiotics for 14 days after the vaccinations.

Exclusion criteria

Exclusion Criteria:

  • Prior eculizumab treatment;
  • Presence or suspicion of active bacterial infection at baseline;
  • Participation in another concurrent clinical study within at least 30 days prior to screening;
  • History of meningococcal/pneumococcal/gonococcal disease;
  • Pregnant, breast feeding, or intending to conceive during the study including the safety follow-up visits;
  • Any other condition that could increase the participant's risk or confound the outcome of the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Eculizumab

    Eculizumab was administered as an IV infusion for 12 weeks. All participants weighed more than 45 kg and received the following weight-based dosing regimen: induction/loading = 600 milligram (mg) weekly x 4; maintenance = 900 mg at Week 5; 900 mg every 2 weeks.

    Drug: Eculizumab

Interventions

  • 5 mg/mL solution in 5% Dextrose

    Also known as: Soliris®

06

What researchers measure

Primary outcomes

  1. Peak And Trough Concentrations Of Eculizumab In Serum At Week 12

    Serum concentrations of eculizumab were measured by using a validated enzyme-linked immunosorbent assay (ELISA) method developed at Alexion Pharmaceuticals Bioanalytical Laboratory. The range of the analytical assay was 10 to 600 microgram per milliliter (μg/mL). Peak concentrations were not measured at the early termination (ET) visit.

    Time frame: Pre-infusion and 1 hour post-infusion at End of Treatment (EOT) (Day 84 [Week 12]) or ET

Secondary outcomes

  1. Number Of Participants With Treatment-emergent Adverse Events (TEAEs)

    A TEAE was defined as any adverse event (AE) not present prior to exposure to eculizumab or any event already present that worsened in either intensity or frequency following exposure to eculizumab. A serious TEAE was defined as any event that resulted in death, was immediately life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect. Related TEAEs were considered by investigators to be definitely, probably, or possibly related to administration of the study drug. Relationship is ordered as follows: unrelated, possibly related, probably related, or definitely related. TEAEs and TEAE severity were classified in accordance with the Medical Dictionary for Regulatory Activities (MedDRA) 13.0 dictionary. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

    Time frame: First dose of study drug (Day 0) to End of Follow-up (Week 20 [8 weeks after EOT])

  2. Area Under The Curve (AUC) Of The Change From Baseline To Week 12 In Levels Of Lactate Dehydrogenase (LDH)

    The AUC of LDH was calculated by using the change of LDH from baseline values for each participant up to Week 12. For those participants with missing LDH values, the last observation carried forward method (LOCF) was used to impute missing values. Individual AUC values of LDH were summarized and tabulated.

    Time frame: Baseline, EOT (Day 84 [Week 12]) or ET

  3. Concentration Of Plasma-free Hemoglobin At Baseline And Week 12

    Plasma-free hemoglobin was determined for each participant by using standard laboratory assays. The values of plasma-free hemoglobin were summarized by visit.

    Time frame: Baseline, EOT (Day 84 [Week 12]) or ET

  4. Change From Baseline In LDH Levels

    Levels of LDH were determined by using standard laboratory assays. LDH values and the change of LDH from baseline were summarized by visit.

    Time frame: Baseline, Weeks 1 to 12 or ET

07

Results

Posted Oct 31, 2018

Participant flow

The recruitment period lasted from October 2009 to January 2011. Three sites in the United States of America enrolled a total of 7 participants with paroxysmal nocturnal hemoglobinuria (PNH).

Participant flow — Overall Study
MilestoneEculizumab
Started7
Induction phase7
Maintenance phase7
Received at least 1 dose of study drug7
Intent-to-treat (itt) population7
Completed7
Not completed0

Outcome measures

PrimaryPeak And Trough Concentrations Of Eculizumab In Serum At Week 12

Serum concentrations of eculizumab were measured by using a validated enzyme-linked immunosorbent assay (ELISA) method developed at Alexion Pharmaceuticals Bioanalytical Laboratory. The range of the analytical assay was 10 to 600 microgram per milliliter (μg/mL). Peak concentrations were not measured at the early termination (ET) visit.

Time frame:
Pre-infusion and 1 hour post-infusion at End of Treatment (EOT) (Day 84 [Week 12]) or ET
Reported as:
Median · μg/mL
Peak And Trough Concentrations Of Eculizumab In Serum At Week 12
μg/mLEculizumab
Trough concentration192.5 (124.2 to 321.1)
Peak concentration425.4 (220.5 to 566.1)
SecondaryNumber Of Participants With Treatment-emergent Adverse Events (TEAEs)

A TEAE was defined as any adverse event (AE) not present prior to exposure to eculizumab or any event already present that worsened in either intensity or frequency following exposure to eculizumab. A serious TEAE was defined as any event that resulted in death, was immediately life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect. Related TEAEs were considered by investigators to be definitely, probably, or possibly related to administration of the study drug. Relationship is ordered as follows: unrelated, possibly related, probably related, or definitely related. TEAEs and TEAE severity were classified in accordance with the Medical Dictionary for Regulatory Activities (MedDRA) 13.0 dictionary. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

Time frame:
First dose of study drug (Day 0) to End of Follow-up (Week 20 [8 weeks after EOT])
Reported as:
Count of participants · Participants
Number Of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsEculizumab
Participants with at least 1 TEAE7
Participants with any serious TEAE2
Participants with any mild TEAE4
Participants with any moderate TEAE1
Participants with any severe TEAE2
Participants with any unrelated TEAE2
Participants with any possibly related TEAE3
Participants with any probably related TEAE2
Participants with any definitely related TEAE0
SecondaryArea Under The Curve (AUC) Of The Change From Baseline To Week 12 In Levels Of Lactate Dehydrogenase (LDH)

The AUC of LDH was calculated by using the change of LDH from baseline values for each participant up to Week 12. For those participants with missing LDH values, the last observation carried forward method (LOCF) was used to impute missing values. Individual AUC values of LDH were summarized and tabulated.

Time frame:
Baseline, EOT (Day 84 [Week 12]) or ET
Reported as:
Mean · Units * Days per Liter (U*Day/L)
Area Under The Curve (AUC) Of The Change From Baseline To Week 12 In Levels Of Lactate Dehydrogenase (LDH)
Units * Days per Liter (U*Day/L)Eculizumab
Area Under The Curve (AUC) Of The Change From Baseline To Week 12 In Levels Of Lactate Dehydrogenase (LDH)-60634 ± 72916
SecondaryConcentration Of Plasma-free Hemoglobin At Baseline And Week 12

Plasma-free hemoglobin was determined for each participant by using standard laboratory assays. The values of plasma-free hemoglobin were summarized by visit.

Time frame:
Baseline, EOT (Day 84 [Week 12]) or ET
Reported as:
Mean · mg per deciliter (mg/dL)
Concentration Of Plasma-free Hemoglobin At Baseline And Week 12
mg per deciliter (mg/dL)Eculizumab
Baseline17.70 ± 19.091
Week 127.44 ± 3.145
SecondaryChange From Baseline In LDH Levels

Levels of LDH were determined by using standard laboratory assays. LDH values and the change of LDH from baseline were summarized by visit.

Time frame:
Baseline, Weeks 1 to 12 or ET
Reported as:
Mean · U/L
Change From Baseline In LDH Levels
U/LEculizumab
Baseline1020 ± 967
Change from baseline at Week 1-672 ± 837
Change from baseline at Week 2-763 ± 916
Change from baseline at Week 3-752 ± 934
Change from baseline at Week 4-761 ± 924
Change from baseline at Week 8-747 ± 904
Change from baseline at Week 12-771 ± 914

Adverse events

Collected over First dose of study drug (Day 0) to End of Follow-up (Week 20 [8 weeks after EOT]). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab—2/7 (28.6%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventEculizumab
MenorrhagiaReproductive system and breast disorders1/4
Vaginal haemorrhageReproductive system and breast disorders1/4
AnaemiaBlood and lymphatic system disorders1/7
Aplastic anaemiaBlood and lymphatic system disorders1/7
ThrombocytopeniaBlood and lymphatic system disorders1/7
HeadacheNervous system disorders1/7
Acute sinusitisInfections and infestations1/7
Catheter site cellulitisInfections and infestations1/7
Otitis media acuteInfections and infestations1/7
Most frequent other events
Showing 10 of 26
Most frequent other events
EventEculizumab
HeadacheNervous system disorders5/7
Abdominal pain upperGastrointestinal disorders2/7
PyrexiaGeneral disorders2/7
Upper respiratory tract infectionInfections and infestations2/7
CoughRespiratory, thoracic and mediastinal disorders2/7
Vaginal dischargeReproductive system and breast disorders1/4
Vulvovaginal pruritusReproductive system and breast disorders1/4
HaemolysisBlood and lymphatic system disorders1/7
Lymph node painBlood and lymphatic system disorders1/7
DiarrhoeaGastrointestinal disorders1/7

Baseline characteristics

ITT Population: Participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Eculizumab
Mean15.01 ± 2.28
Age, Customized
Age, Customized(Participants)Eculizumab
Children (2 to 11 years)1
Adolescents (12 to 17 years)6
Sex: Female, Male
Sex: Female, Male(Participants)Eculizumab
Female4
Male3
08

Study locations

3 sites
  • Orange, California 92868, United States
  • Pensacola, Florida 32504, United States
  • Memphis, Tennessee 38105, United States
09

References and documents

Publications

  • Reiss UM, Schwartz J, Sakamoto KM, Puthenveetil G, Ogawa M, Bedrosian CL, Ware RE. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatr Blood Cancer. 2014 Sep;61(9):1544-50. doi: 10.1002/pbc.25068. Epub 2014 Apr 29. PubMed 24777716 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2009 to primary completion in May 2011, 19 months.

Results were first posted in Oct 2018, 7 years 5 months after primary completion. A results delay was requested in Mar 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2009
First posted
Mar 24, 2009
StartActual
Oct 2, 2009
Primary completionActual
May 12, 2011
CompletionActual
May 12, 2011
Results delay requested
Mar 9, 2017
Results first posted
Oct 31, 2018
Last update
Oct 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00867932
Responsible party
Sponsor
First posted
Mar 24, 2009
Start date
Oct 2, 2009
Primary completion
May 12, 2011
Completion
May 12, 2011
Results posted
Oct 31, 2018
Last update
Oct 31, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion